Skip to main content
. 2018 Jan 25;25(4):381–391. doi: 10.1530/ERC-17-0449

Figure 4.

Figure 4

LXR agonist GW3965 activates LXRE-dependent transcription and alters proliferation in endometrial epithelial cancer cells. The impact of the LXR synthetic agonist GW3965 on LXRE-dependent transcription (A, B and C) and on cell proliferation (D, E and F) was assessed in endometrial cancer cell lines; Ishikawa, RL95 and MFE280. GW3965 significantly increased LXRE-dependent transcription in a dose-dependent manner in each endometrial cancer cell line. GW3965 significantly increased LXRE-dependent transcription at all concentrations assessed and was maximally increased by 10−6 M GW3965 in Ishikawa cells (P < 0.0001) (A) and RL95 cells (P < 0.01) (B). LXRE-dependent transcription and was not increased by 10−8 M GW3965 but maximally increased by 10−5 M 27HC (P < 0.001) in MFE280 cells (C). Cell proliferation was assessed by CyQuant direct proliferation assay in each cell line (D, E and F). Proliferation of Ishikawa cells was increased by 10−8 M (P < 0.01) and by 10−5 M 27HC (P < 0.01) (D). In contrast, proliferation of RL95 cells was decreased by 10−8 M (P < 0.001), 10−7 M (P < 0.001), 10−6 M (P < 0.01) and 10−5 M (P < 0.05) GW3965 (E). Proliferation of MFE280 cells was decreased by 10−8 M (P < 0.001), 10−7 M (P < 0.0001), 10−6 M (P < 0.0001) and 10−5 M (P < 0.05) GW3965 (I). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. One sample t test and a theoretical mean of 1. All data are presented as mean ± s.e.m.